{"nctId":"NCT01185704","briefTitle":"Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)","startDateStruct":{"date":"2008-11"},"conditions":["Polycystic Ovarian Syndrome"],"count":136,"armGroups":[{"label":"Day 1 protocol","type":"EXPERIMENTAL","interventionNames":["Drug: Cetrorelix acetate","Drug: Recombinant Human Choriogonadotropin (r-hCG)","Drug: Recombinant human follicle stimulating hormone (r-hFSH)"]},{"label":"Day 7 protocol","type":"EXPERIMENTAL","interventionNames":["Drug: Cetrorelix acetate","Drug: Recombinant Human Choriogonadotropin (r-hCG)","Drug: Recombinant human follicle stimulating hormone (r-hFSH)"]}],"interventions":[{"name":"Cetrorelix acetate","otherNames":["Cetrotide®"]},{"name":"Cetrorelix acetate","otherNames":["Cetrotide®"]},{"name":"Recombinant Human Choriogonadotropin (r-hCG)","otherNames":["Ovitrelle®"]},{"name":"Recombinant human follicle stimulating hormone (r-hFSH)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female subjects with PCO or Polycystic ovary syndrome (PCOS) according to the revised 2003 Rotterdam Consensus\n* Female subjects suitable for IVF/ICSI, undergoing first or second attempt\n* 18-35 years old, Body Mass Index (BMI) less than or equal to 32, non-smoking at least from Visit 0 (V0)\n* Normal FSH value (less than 10 international unit per liter \\[IU/L\\]) on Day 3 of spontaneous cycle within 12 months prior to the trial\n* Anti Mullerian Hormone (AMH) value (greater than 1.5 nanogram per milliliter \\[ng/mL\\]) of a spontaneous cycle within 12 months prior to the trial or at least at V0\n* No history of active genito-urinary infection\n* Normal thyroid function (or adequate substitution for at least 3 months)\n* Negative cervical papanicolaou test within the last 12 months prior to study entry\n* No gonadotropins, for at least one month prior to the trial\n* No metformin therapy for at least one month prior to Visit 1 (V1)\n* Subject who is able to participate in the trial and has provided written, informed consent.\n\nExclusion Criteria:\n\n* Ongoing pregnancy, any pregnancy within 3 months prior to study entry, or any contraindication to pregnancy or carrying pregnancy to term\n* Drilling 3 months prior to V0\n* Uterine malformation, diethylstilbestrol syndrome, synechia\n* Female subjects with World Health Organization (WHO) Type I or III anovulation\n* Female subjects with hyperprolactinemia\n* Female subjects with more than 2 recurrent miscarriages (early or late, and for any reasons)\n* Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or C virus, for subject or partner\n* Abnormal gynecological bleeding of undetermined origin\n* History of major thromboembolic disease\n* Endometriosis (Grade III or IV)\n* Presence or history of malignant tumors and related treatment\n* Known case of tumors of the hypothalamus or pituitary gland\n* Clinically significant systemic disease or clinically significant abnormal hematology, chemistry, or urinalysis results at screening\n* Known allergic reaction or hypersensitivity to Cetrotide® or Ovitrelle®\n* Any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years\n* Participation in another clinical trial within 3 months prior to study entry.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"35 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Estradiol (E2) Levels on r-hCG Day","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1668.86","spread":"862.62"},{"groupId":"OG001","value":"1672.80","spread":"835.49"}]}]}]},{"type":"SECONDARY","title":"Serum Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.87","spread":"4.62"},{"groupId":"OG001","value":"6.84","spread":"3.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.98","spread":"1.54"},{"groupId":"OG001","value":"6.69","spread":"10.29"}]}]}]},{"type":"SECONDARY","title":"Serum Estradiol (E2) Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.42","spread":"14.06"},{"groupId":"OG001","value":"68.79","spread":"116.09"}]}]}]},{"type":"SECONDARY","title":"Serum Progesterone (P4) Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.72"},{"groupId":"OG001","value":"0.97","spread":"1.82"}]}]}]},{"type":"SECONDARY","title":"Anti Mullerian Hormone (AMH) Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.27","spread":"4.40"},{"groupId":"OG001","value":"7.18","spread":"4.11"}]}]}]},{"type":"SECONDARY","title":"Number of Follicles Greater Than or Equal (>=) to 17 mm (For Day 1 Protocol) or 19 mm (For Day 7 Protocol) on r-hCG Day","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.55","spread":"2.20"},{"groupId":"OG001","value":"2.49","spread":"1.99"}]}]}]},{"type":"SECONDARY","title":"Number and Quality of Oocytes Retrieved","description":"Oocyte retrieval is a technique used in in-vitro fertilization (IVF) in order to remove oocytes from the ovary of the female participant, enabling fertilization outside the body. Oocytes were classified into 4 different categories based on their quality: mature, fractured, immature and inseminated oocytes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.48","spread":"5.21"},{"groupId":"OG001","value":"8.11","spread":"5.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.52","spread":"4.07"},{"groupId":"OG001","value":"3.72","spread":"4.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.34"},{"groupId":"OG001","value":"0.11","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"2.29"},{"groupId":"OG001","value":"1.38","spread":"2.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.06","spread":"4.14"},{"groupId":"OG001","value":"4.52","spread":"4.66"}]}]}]},{"type":"SECONDARY","title":"Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1462.50","spread":"537.85"},{"groupId":"OG001","value":"1221.35","spread":"478.31"}]}]}]},{"type":"SECONDARY","title":"Percentage of Fertilized Oocytes Retrieved","description":"Oocytes were fertilized using Intra-cytoplasmic Sperm Injection (ICSI) technique which is an IVF procedure in which a single sperm is injected directly into an egg under a microscope.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.22","spread":"30.66"},{"groupId":"OG001","value":"46.86","spread":"30.54"}]}]}]},{"type":"SECONDARY","title":"Number of Embryos","description":"Embryo is defined as the product of the zygote, two or three days after fertilization of the oocytes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.18","spread":"3.18"},{"groupId":"OG001","value":"3.60","spread":"3.27"}]}]}]},{"type":"SECONDARY","title":"Number of Blastocysts","description":"Blastocyst is an embryo, five or six days after fertilization, with an inner cell mass, outer layer of trophectoderm and a fluid-filled blastocoele cavity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.26","spread":"1.05"},{"groupId":"OG001","value":"0.20","spread":"0.90"}]}]}]},{"type":"SECONDARY","title":"Number of Transferred Embryos","description":"Embryo transfer is the procedure in which one or more embryos are placed in the uterus.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":"0.74"},{"groupId":"OG001","value":"1.02","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"Implantation Rate","description":"Implantation rate per reporting group was measured as the number of gestational sacs observed, divided by the number of embryos transferred multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.90","spread":null},{"groupId":"OG001","value":"32.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Pregnancy","description":"Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It excludes ectopic pregnancy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. A Serious Adverse Event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. To avoid the participant/event combination double-count AEs and SAEs are reported separately.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":65},"commonTop":["Headache","Pelvic pain","Ovarian Hyperstimulation syndrome","Nausea","Injection site erythema"]}}}